Alps Advisors Inc. raised its position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 9.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,720 shares of the biopharmaceutical company’s stock after purchasing an additional 2,147 shares during the quarter. Alps Advisors Inc. owned 0.10% of Intercept Pharmaceuticals worth $1,435,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sphera Funds Management LTD. raised its position in Intercept Pharmaceuticals by 100.0% in the second quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $3,632,000 after purchasing an additional 15,000 shares during the period. Vanguard Group Inc. raised its position in Intercept Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after purchasing an additional 57,149 shares during the period. Dynamic Technology Lab Private Ltd raised its position in Intercept Pharmaceuticals by 85.6% in the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock valued at $824,000 after purchasing an additional 3,136 shares during the period. Geode Capital Management LLC raised its position in Intercept Pharmaceuticals by 12.8% in the first quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock valued at $16,301,000 after purchasing an additional 16,392 shares during the period. Finally, Asymmetry Capital Management L.P. purchased a new stake in Intercept Pharmaceuticals in the second quarter valued at approximately $3,580,000. 78.02% of the stock is currently owned by institutional investors.

A number of brokerages have issued reports on ICPT. Wedbush reissued an “outperform” rating and issued a $253.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, August 25th. Royal Bank Of Canada boosted their target price on Intercept Pharmaceuticals from $200.00 to $244.00 and gave the company an “outperform” rating in a research report on Tuesday, September 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th. Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price objective (up previously from $60.00) on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $135.00 price objective (down previously from $275.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Intercept Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $153.76.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/13/intercept-pharmaceuticals-inc-icpt-shares-bought-by-alps-advisors-inc.html.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded down $3.39 during midday trading on Monday, reaching $60.26. 1,266,800 shares of the company’s stock traded hands, compared to its average volume of 779,853. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95. Intercept Pharmaceuticals, Inc. has a one year low of $54.98 and a one year high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The company had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. During the same quarter in the prior year, the firm posted ($3.59) earnings per share. Intercept Pharmaceuticals’s revenue for the quarter was up 697.9% on a year-over-year basis. sell-side analysts anticipate that Intercept Pharmaceuticals, Inc. will post -13.41 EPS for the current fiscal year.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 253 shares of the company’s stock in a transaction on Friday, August 25th. The shares were sold at an average price of $111.31, for a total value of $28,161.43. Following the completion of the transaction, the insider now owns 23,324 shares in the company, valued at $2,596,194.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO David Shapiro sold 1,250 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $117.43, for a total transaction of $146,787.50. Following the completion of the transaction, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at approximately $5,379,703.16. The disclosure for this sale can be found here. Insiders sold 4,069 shares of company stock valued at $325,974 in the last 90 days. 4.50% of the stock is currently owned by insiders.

Intercept Pharmaceuticals Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.